CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
0.01% bimatoprostdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01271686
NCT01271686Phase 4Completed
CompareCT.gov

24-hour IOP-lowering Effect of 0.01% Bimatoprost

University of California, San Diego·interventional·Posted Jan 7, 2011·Updated Jun 19, 2014

In Brief

A Phase 4 clinical trial evaluating 0.01% bimatoprost for Intraocular Pressure and 2 related conditions. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study will evaluate the 24-hour IOP-lowering efficacy of 0.01% bimatoprost once daily in patients with glaucoma or ocular hypertension

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Pressure, Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 7, 2011
Enrollment StartJan 1, 2011
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.5 years ago

Interventions

0.01% bimatoprostdrug

0.01% bimatoprost once in the evening for 4 weeks